Objective-Epoxyeicosatrienoic acids (EETs) have antiinflammatory effects and are required for normal endothelial function. The soluble epoxide hydrolase (sEH) metabolizes EETs to their less active diols. We hypothesized that knockout and inhibition of sEH prevents neointima formation in hyperlipidemic ApoE Ϫ/Ϫ mice. Methods and Results-Inhibition of sEH by 12-(3-adamantan-1-yl-ureido) dodecanoic acid or knockout of the enzyme significantly increased plasma EET levels. sEH activity was detectable in femoral and carotid arteries. sEH knockout or inhibition resulted in a significant reduction of neointima formation in the femoral artery cuff model but not following carotid artery ligation. Although macrophage infiltration occurred abundantly at the site of cuff placement in both sEH ϩ/ϩ and sEH Ϫ/Ϫ , the expression of proinflammatory genes was significantly reduced in femoral arteries from sEH Ϫ/Ϫ mice. Moreover, an in vivo 5-bromo-2Ј-deoxyuridine assay revealed that smooth muscle cell proliferation at the site of cuff placement was attenuated in sEH knockout and sEH inhibitor-treated animals. Conclusion-These observations suggest that inhibition of sEH prevents vascular remodeling in an inflammatory model but not in a blood flow-dependent model of neointima formation. (Arterioscler Thromb Vasc Biol. 2010;30:909-914.)
N eointima formation is an important clinical problem contributing to vaso-occlusive diseases, such as restenosis after coronary angioplasty or atherosclerosis. The process is complex and, at least in rodents, involves proliferation of smooth muscle cells (SMCs) in response to growth factors (such as platelet-derived growth factor), migration of SMCs into the subendothelial layer, 1 and recruitment of monocytes and transdifferentiation of circulating progenitor cells at the site of the lesion. 2 Many systemic and local factors modulate these events. Mechanical injury, inflammation, oxidative stress, 3 and hyperlipidemia promote neointima formation, whereas nitric oxide (NO), generated by either endothelial or inducible NO synthases, attenuates neointima formation. 4 Several different models of neointima development can be studied in rodents. In almost every model, hyperlipidemia, induced by fat feeding or genetic deletion of the low-density lipoprotein receptor or apolipoproteins, is a prerequisite for neointima formation, which is then combined with a second stimulus. 5 Such a second stimulus is usually an alteration in blood flow and subsequent changes in local endothelial NO production, as it occurs in the carotid artery ligation model 6 ; mechanical injury and endothelial denudation, as in the oversized balloon model; or vascular irritation induced by a foreign body, as in the femoral artery cuff model. 4 Although all of these interventions promote neointima formation, the degree of inflammation and the contribution of NO to the process vary considerably. In general, the femoral artery cuff model is considered more inflammatory than the carotid ligation model, the latter being dominated by NO withdrawal.
Nitric oxide, however, is not the only vasoprotective endothelial autacoid. Prostacyclin and epoxyeicosatrienoic acids (EETs) also contribute to the antiatherosclerotic properties of the endothelium. Indeed, EETs, which are derived from arachidonic acid by epoxygenation through cytochrome P450 monooxygenases, mediate endothelium-dependent vasodilation, promote angiogenesis, and have antiinflammatory properties. 7 The availability of EETs is limited primarily by the soluble epoxide hydrolase (sEH), which metabolizes EETs to their corresponding dihydroxyeicosatrienoic acids (DHETs). DHETs show equivalent or reduced biological activity but are more hydrophilic and easily excreted. 8 sEH inhibitors lower blood pressure in different models of hypertension in rodents. 9, 10 Moreover, these compounds attenuate the inflammatory response in models of endotoxemia and acute lung injury, as well as ischemic injury in stroke models in rats.
The role of vascular-derived EETs in the process of neointima formation is unknown and we hypothesized that increasing EET levels by inhibiting the sEH should attenuate neointima formation in hyperlipidemic ApoE Ϫ/Ϫ mice following placement of a femoral artery cuff and carotid artery ligation. The role of sEH was studied by generating sEH-ApoE double knockout mice and by the treatment with the sEH inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA).
Materials and Methods
An extended version of the Materials and Methods section can be found in the supplemental materials, available online at http://atvb.ahajournals.org.
Animal Models
The experiments were performed in accordance with the National Institutes of Health Guidelines on the Use of Laboratory Animals. Both the University Animal Care Committee and the Federal Authorities for Animal Research of the Regierungspräsidium Darmstadt (Hessen, Germany) approved the study protocol. C57/BL6-ApoE Ϫ/Ϫ breeding pairs (ApoE Ϫ/Ϫ ) were purchased from Charles River (Deisenhofen, Germany). C57/BL6-sEH Ϫ/Ϫ mice (F5, sEH Ϫ/Ϫ ) were kindly supplied by F. Gonzalez (National Institutes of Health, Bethesda, Md) 11 and crossed with ApoE Ϫ/Ϫ mice to obtain ApoE Ϫ/Ϫ ϫsEH Ϫ/Ϫ animals. ApoE Ϫ/Ϫ ϫsEH Ϫ/Ϫ were backcrossed more than 7 times to obtain ApoE Ϫ/Ϫ ϫsEH ϩ/ϩ . For the sake of readability, ApoE Ϫ/Ϫ ϫsEH ϩ/ϩ are designated ApoE Ϫ/Ϫ . The sEH inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA; final concentration, 100 mg/L) 12 was administered to the animals via drinking water. Neointima formation and accelerated atherosclerosis were induced by means of vascular injury through cuff placement around the femoral artery of mice or left common carotid artery ligation, as described previously. 4 -6 Two weeks after cuff placement, respectively 4 weeks after carotid artery ligation, vessels were perfusion fixed, sectioned and analyzed by planimetry. In vivo cell proliferation was determined by 5-bromo-2Ј-deoxyuridine (BrdUrd) incorporation.
sEH and EET Detection
sEH protein was detected by Western blot analysis, whereas activity was determined by the conversion of 14,15-EET to 14,15-DHET. EETs and DHETs were measured by liquid chromatography-tandem mass spectrometry as described previously. 13
Data and Statistical Analysis
All values are meanϮSEM. Statistical analysis was performed using ANOVA, unpaired t test, and the Mann-Whitney test. A probability value of less than 0.05 was considered statistically significant.
Results

Loss of sEH Activity Attenuates Neointima Formation in the Femoral Artery Cuff Model
Two weeks after cuff placement, a marked neointima had developed in the femoral artery of ApoE Ϫ/Ϫ mice. In animals with genetic deletion or pharmacological inhibition of the sEH, the intima-media ratio was approximately 50% lower than in control animals ( Figure 1 ). The outer vessel diameter as a parameter of inward or outward remodeling was, however, identical in all groups, demonstrating that a lack of sEH activity leads to attenuation of neointima formation in the femoral cuff model in ApoE Ϫ/Ϫ mice.
sEH Knockout Has No Effect on Neointima Formation Following Carotid Artery Ligation
In contrast to the data obtained in the femoral artery cuff model, genetic deletion of the sEH had no effect on neointima formation after carotid artery ligation. In ligated vessels, there was no difference in the intima-media ratio or in the constrictive remodeling between ApoE Ϫ/Ϫ and ApoE Ϫ/Ϫ ϫsEH Ϫ/Ϫ mice ( Figure 2 ). Given this negative result, the effect of sEH inhibition on neointima formation in this model was not tested in additional animal experiments. Figure I) , as well. These data demonstrate that lack of sEH activity systematically increases the EET-DHET ratio, acutely as well as chronically, and that there is no local loss of sEH activity in both models that were used in this study.
Loss of sEH Activity Attenuates SMC Proliferation in the Femoral Artery Cuff Model
Neointima formation is, at least in part, a consequence of local proliferation and migration of SMCs. Indeed, immunohistology of operated femoral arteries revealed that the neointima in the cuff model consists mainly of smooth ␣-actin immunopositive cells, covered by an intact endothelium, as determined by platelet endothelial cell adhesion molecule 1 (PECAM-1) staining ( Figure 4A ). Macrophages or endothelial cells were almost absent in the neointima ( Figure 4A ). BrdUrd labeling showed a significant increase of SMC proliferation in response to femoral artery cuff placement and carotid artery ligation ( Figure 4B through 4D). SMC proliferation in response to cuff placement was significantly attenuated in the femoral of ApoE Ϫ/Ϫ mice treated with the sEH inhibitors compared with solvent-treated animals ( Figure 4B ). Moreover, SMC proliferation was also significantly lower in the cuffed region of femoral arteries of ApoE Ϫ/Ϫ ϫsEH Ϫ/Ϫ mice compared with ApoE Ϫ/Ϫ animals ( Figure 4C ). In line with the data on neointima formation, SMC proliferation in ligated carotid arteries was not affected by genetic deletion of the sEH ( Figure 4D ).
Genetic Deletion of the sEH Attenuates the Inflammatory Response in the Femoral Artery Cuff Model
As also obvious from the hematoxylin/eosin staining in Figures 1 and 2 , the femoral artery cuff model, but not the carotid artery ligation model, presents with a marked adventitial inflammatory infiltrate ( Figure 5A ). As EETs have antiinflammatory effects, we concentrated on this aspect in the femoral artery model as a potential explanation for the antiproliferative effect of sEH inhibition. As determined by area coverage, the adventitial macrophage infiltrate was similar in ApoE Ϫ/Ϫ and ApoE Ϫ/Ϫ ϫsEH Ϫ/Ϫ mice. Also, sEH inhibitor treatment had no significant effect on macrophage accumulation. In contrast, the sEH controlled the expression of some markers of inflammation: Gro-␤ and COX2 mRNA was significantly lower, and there was a trend toward a reduced connective tissue growth factor (CTGF) mRNA expression in sEH Ϫ/Ϫ ϫApoE Ϫ/Ϫ mice compared with ApoE Ϫ/Ϫ mice ( Figure 5B) . No difference between ApoE Ϫ/Ϫ and ApoE Ϫ/Ϫ ϫsEH Ϫ/Ϫ was observed for expression of tumor necrosis factor-␣ (2.8Ϯ0.3 versus 2.5Ϯ0.5), Gro-␣ (7.0Ϯ1.2 versus 5.8Ϯ1.0), and MCP-1 (1.9Ϯ0.1 versus 1.7Ϯ0.2). Moreover, no differences in mRNA expression were observed between the groups in the carotid artery ligation model (data not shown).
Discussion
In the present study, we determined the role of the sEH in neointima formation in ApoE Ϫ/Ϫ mice. In the femoral artery cuff model, we observed that lack of sEH activity was associated with attenuated neointima formation, reduced SMC proliferation, and attenuated proinflammatory gene expression. In contrast, in the carotid artery ligation model, no effect of genetic deletion of the sEH was observed.
EETs are potent endogenous compounds with beneficial vascular actions. 7 Because the sEH limits EET availability, inhibition of this enzyme has emerged as an option for treating vascular diseases. Animal experiments, which were almost exclusively performed in rodents, suggested that sEH inhibition lowers blood pressure in some hypertensive models 9, 11 and that a reduction of sEH activity has antiinflammatory effects in a variety of disease conditions. 14 Thus, we hypothesized that sEH inhibition should strongly prevent neointima formation.
It was therefore an unexpected finding that the lack of sEH activity interfered with the neointima development only in the femoral cuff model and not in the carotid artery ligation model. The latter observation is strengthened by the recent report that the ligation-induced remodeling of the carotid artery is also sEH independent. 15 The carotid artery ligation model and the femoral artery cuff model, however, differ in their consequences on NO formation, the site of injury, and the accompanying processes in the adventitia. For example, the carotid ligation artery model, but not the femoral cuff model, is devoid of shear stress-induced NO release. Thus, in the latter model, genetic knockout of the endothelial nitric oxide synthase promoted disease progression. 4 Moreover, the femoral cuff model exhibits high inflammatory activity, as it was made evident by the induction of inducible nitric oxide synthase, 4 and increased tumor necrosis factor-␣ expression. 16 Accordingly, inflammatory components are of central relevance for neointima formation since direct stimulation with the toll-like receptor 4 ligand lipopolysaccharide further increased neointima formation in the femoral artery cuff model, 17 and corticosteroids attenuated it. 18 The pathophysiology of neointima formation in response to carotid artery ligation also involves endothelial activation, inflammation, and cytokine production, 3, 19, 20 but the withdrawal of flow-induced production of endothelium-derived NO is considered to be the main stimulus. 21 In addition, pronounced apoptosis of SMCs occurs within the first 2 days after the intervention. 22 For other vascular injury models, it has been demonstrated that the extent of the subsequent proliferation of SMCs in the media occurs in relation to the extent of SMC apoptosis. 23 Apoptotic cells also have strong antiinflammatory properties, as they induce M2 macrophage polarization. 24 This mechanism may limit the inflammation in the carotid ligation model. Although the present study did not focus on apoptosis, it is conceivable that the pronounced antiinflammatory effects of sEH inhibitors are less effective in the carotid ligation model or that sEH inhibitors interfere with the apoptotic process.
Given that NO production is increased in the femoral cuff model, it should be mentioned that NO appears to play a major role in mediating the biological effects of EETs in the mouse. 25 EETs activate the phosphatidylinositol 3-kinase, 26 increase via AKT the activity of endothelial nitric oxide synthase, and protect endothelial cells from apoptosis. Importantly, knockout of sEH has also been shown to increase phosphatidylinositol 3-kinase activity, which protected cardiac function after ischemia. 27 Moreover, it has recently been shown that the beneficial effects of sEH inhibition are not observed in the wire-injury-induced vascular remodeling model of the femoral artery in C57BL/6 mice, which is characterized by endothelial denudation. 15 A large number of studies have supported the hypothesis that sEH inhibition exerts beneficial vascular and antiinflammatory effects. Accordingly, in the present work, attenuated neointima formation in femoral arteries of sEH Ϫ/Ϫ and sEH inhibitor-treated mice was associated with reduced proliferation of cells in the media of the vessels, as well as attenuated expression of COX2, CTGF, and Gro-␤. Interestingly, expression of tumor necrosis factor-␣, which is derived primarily from macrophages, was unaffected by the lack of sEH. This suggests some specificity of the antiinflammatory property of EETs. It has been suggested that EETs directly interfere with the activation of nuclear factor B 28 in the vasculature, and such a process would affect COX2 and Gro-␤ expression, as also observed in the present study. Both proteins could contribute to neointima formation through a chemotactic and proinflammatory effect. The control of the CTGF expression is complex and predominantly involves transforming growth factor ␤, hypoxia, and mechanical stress. 29 In addition to its profibrotic effects, CTGF promotes proliferation, 29 and thus attenuated CTGF expression in femoral arteries of animals which lack sEH could contribute to attenuated SMC proliferation observed in this group. Alternatively, as previously noted in cultured SMCs, sEH inhibition can attenuate the proliferation of SMCs by a direct effect on the cell cycle. 30 The final step of neointima formation involves the migration of SMCs from the medial layer into the subintimal space. It was previously demonstrated in rat SMCs that EETs attenuate migration activity in a transwell assay. 31 Nevertheless, in the present study, a specific antimigratory effect of EETs on murine aortic vascular SMCs was not observed, as DHETs were as effective as EETs in preventing migration in cultured cells (data not shown). This suggests that in vivo complex secondary effects, potentially via the action of NO, contribute to the actions of EETs or that local concentrations in the model vary from those used in culture systems and derived from plasma level determinations. Indeed, a limitation of the present study was that EETs and DHETs were only measured in the plasma, but even with pooling samples it was not possible to obtain sufficient tissue for reliable mass spectroscopy analyses.
It has been suggested that sEH inhibitors also reduce the progression of atherosclerotic disease in ApoE Ϫ/Ϫ mice. 32 Although this finding might not be unexpected on the basis of our observations, it should be mentioned that the proatherosclerotic protocol used in the latter study involved the chronic infusion of angiotensin II in combination with an atherogenic diet. Angiotensin II, however, induces strong vascular inflammation, 33 and a high-fat diet aggravates the situation by inducing fatty liver inflammation. 34 Thus, the "antiatherosclerotic" action might rather be an antiinflammatory one, and additional experiments in "aged" ApoE Ϫ/Ϫ and ApoE Ϫ/Ϫ ϫ sEH Ϫ/Ϫ mice, as well as population-based studies on the different sEH polymorphisms, will be needed to uncover the true contribution of sEH to this disease.
In conclusion, in the present study we provide evidence that the beneficial vascular effects of sEH inhibition extend beyond the pressure-lowering effect and that sEH inhibitors may be attractive therapeutics for attenuating neointima formation in some disease conditions.
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